Evidence map›Paper›PMID 39823116›Full record

ArticleFree neuropathology2024

Neurodegeneration: 2024 update.

John F Crary

Abstract read
In one paragraph

Article in Free neuropathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Alzheimer's disease in theFree neuropathology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

John F CraryDepartment of Pathology, Nash Family Department of Neuroscience, Department of Artificial Intelligence & Human Health, Neuropathology Brain Bank & Research CoRE, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review highlights a collection of both diverse and highly impactful studies published in the previous year selected by the author from the neurodegenerative neuropathology literature. As with previous reviews in this series, the focus is, to the best of my ability, to highlight human tissue-based experimentation most relevant to experimental and clinical neuropathologists. A concerted effort was made to balance the selected studies across neurodegenerative disease categories, approaches, and methodologies to capture the breadth of the research landscape. These studies employ a range of classical and state-of-the-art methodologies ranging from clinical pathoanatomical correlative studies to single-cell RNA sequencing, artificial intelligence, and patient-derived human induced pluripotent stem cell models. Key studies include demonstration of the earliest pathological changes in young patients with repetitive head impacts (RHI), elucidation of the longitudinal trajectory of extrapyramidal symptoms in Lewy body disease subtypes, mapping of cell-type specific polygenic risk in Alzheimer's disease to neuropathology, a novel measure of histological brain age acceleration using artificial intelligence, trends in cerebrovascular pathologies over 25 years, associations between RHI and TDP-43 / hippocampal sclerosis, microglia / T-cell interaction in neurodegeneration, the impact of viral exposures on neurodegenerative disease risk, and polyglutamine repeat expansion disorders. This sampling of the literature collectively displays the breadth of the progress being made in the neuropathology of neurodegenerative diseases.

Indexed as

AgingAlzheimer’s diseaseNeurodegenerationNeuropathologyTauopathyTDP-43 proteinopathyTraumatic brain injuryα-synucleinopathy

Identifiers

PMID39823116
PMCPMC11736941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.